In the studies, the sensor will automatically collect and record data on the inhaler’s usage, wirelessly transmitting the information to a central data repository for analysis by GSK’s clinical researchers. The technology will be used to provide greater insights into adherence patterns across patient populations and may allow for more precise correlation of adherence with safety, efficacy and economic outcomes.
GSK on its end will retain an option to negotiate exclusive commercialization rights to the sensor for use with its portfolio of respiratory medicines administered using the Ellipta inhaler.
“Together [with GSK] we aim to combine our expertise to empower patients and positively impact care,” said David Van Sickle, CEO and co-founder of Propeller.
Propeller’s FDA-cleared platform has been used by patients in over 35 commercial programs across the U.S.The Propeller platform has been used by patients in over 35 commercial programs across the United States, including major healthcare systems, payers, employers and other commercial partners. It is compatible with the majority of commonly used asthma and COPD inhaler devices including controller and reliever metered dose inhalers (MDIs), and other inhaler devices (dry powder inhaler – DPI, and soft mist inhaler – SMI).
The Propeller platform has received FDA 510(k) class II clearance to measure and improve medication adherence, help predict exacerbations, and help reduce the frequency of symptoms and exacerbations in asthma and COPD.